Drugs / pentazocine

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) TALWIN 50 1969-02-03 fda.gov

Trials 5 · a red edge is where a trial was stopped

1968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02070718 Jan → Jul 2013 University of Washington Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00125931 Sep 2005 → Aug 2008 bipolar disorder Mclean Hospital Completed No outcome recorded
Phase 42 trials
Phase 4 NCT02094339 Mar 2014 → Jun 2016 Guangzhou General Hospital of Guangzhou Military Command Unknown No outcome recorded
Phase 4 NCT02114463 Mar 2014 → Aug 2016 Guangzhou General Hospital of Guangzhou Military Command Unknown No outcome recorded
Phase not applicable1 trial
NCT05565274 Oct 2022 → Feb 2023 Federal Medical Centre, Yenagoa Unknown No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00431184 Comparator Jan 2007 → Mar 2011 manic bipolar affective disorder, schizoaffective disorder Mclean Hospital Completed No outcome recorded
Phase 42 trials
Phase 4 NCT02208596 Background Sep 2014 → Feb 2015 Third Affiliated Hospital of Zhengzhou University Unknown No outcome recorded
Phase 4 NCT01872494 Comparator May 2013 → Feb 2014 Guangzhou General Hospital of Guangzhou Military Command Completed No outcome recorded
Phase not applicable1 trial
NCT04539249 Comparator Nov 2020 → Mar 2021 Olakunle Ifeoluwa Makinde Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Pentazocine “To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.” NCT02070718
8

“flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02094339

“flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02114463

“The effects of pentazocine, a kappa agonist, in patients with mania.” PMID 17897484 Sep 2007

NCT04539249

NCT02208596

NCT01872494

NCT05565274

NCT00431184

Action Activate “pentazocine, a kappa agonist” PMID 17897484 Sep 2007
Route Oral “To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.” NCT02070718